Second generation androgen receptor antagonists and challenges in prostate cancer treatment
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Second generation androgen receptor antagonists and challenges in prostate cancer treatment
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 13, Issue 7, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-07-21
DOI
10.1038/s41419-022-05084-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer
- (2022) Anthony V. Serritella et al. CLINICAL CANCER RESEARCH
- Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial
- (2022) Xiaojian Qin et al. BMC Medicine
- Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer
- (2022) Lillian Y Lai et al. JNCI-Journal of the National Cancer Institute
- Proteolysis-targeting chimeras (PROTACs) in cancer therapy
- (2022) Xinyi Li et al. Molecular Cancer
- Development of an LC-MS/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies
- (2022) Thi-Thao-Linh Nguyen et al. MOLECULES
- Development of novel androgen receptor antagonists based on the structure of darolutamide
- (2022) Qian Xu et al. BIOORGANIC CHEMISTRY
- Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer
- (2021) Ali Ghoochani et al. CANCER RESEARCH
- Hormonal Therapy for Prostate Cancer
- (2021) Kunal Desai et al. ENDOCRINE REVIEWS
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor
- (2021) Mariia Radaeva et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Safety of concomitant therapy with radium‐223 and abiraterone or enzalutamide in a real‐world population
- (2021) Hanson Zhao et al. PROSTATE
- Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide
- (2021) Giuseppe Di Lorenzo et al. Clinical Genitourinary Cancer
- Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy
- (2021) Scott Wilkinson et al. EUROPEAN UROLOGY
- Proliferating cell nuclear antigen directly interacts with androgen receptor and enhances androgen receptor‑mediated signaling
- (2021) Shan Lu et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Treatment and trials in non-metastatic castration-resistant prostate cancer
- (2021) Soum D. Lokeshwar et al. Nature Reviews Urology
- Resistance to second-generation androgen receptor antagonists in prostate cancer
- (2021) Keith T. Schmidt et al. Nature Reviews Urology
- Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration‐resistant prostate cancer patients during abiraterone/enzalutamide treatment
- (2021) Cem Onal et al. PROSTATE
- Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity
- (2021) Kirsi Ketola et al. CANCER RESEARCH
- Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis
- (2021) Alessandro Rizzo et al. Expert Opinion on Drug Metabolism & Toxicology
- Radium‐223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration‐Refractory Prostate Cancer: Final Safety and Efficacy Results
- (2021) Benjamin L. Maughan et al. ONCOLOGIST
- A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
- (2021) Stephanie I. Kim et al. PLoS One
- Selective degradation of AR-V7 to overcome castration resistance of prostate cancer
- (2021) Yuan Liu et al. Cell Death & Disease
- Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
- (2021) S. Taavitsainen et al. Nature Communications
- CRISPR-Cas13 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research
- (2021) Fahreddin Palaz et al. ACS Synthetic Biology
- AR Splicing Variants and Resistance to AR Targeting Agents
- (2021) Mayuko Kanayama et al. Cancers
- Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients
- (2021) Nada Lallous et al. Cancers
- Identification and Validation of a Prognostic Signature for Prostate Cancer Based on Ferroptosis-Related Genes
- (2021) Huan Liu et al. Frontiers in Oncology
- Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer
- (2021) Elena S. Martens‐Uzunova et al. Journal of Extracellular Vesicles
- MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer
- (2021) Sanjeev Kumar Srivastava et al. BRITISH JOURNAL OF CANCER
- A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer
- (2021) Corinne Maurice-Dror et al. INVESTIGATIONAL NEW DRUGS
- Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
- (2021) Gerhardt Attard et al. LANCET
- Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
- (2021) Yoshitaka Sekine et al. Oncology Letters
- Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies
- (2021) Aasems Jacob et al. Cancers
- Identifying a Ferroptosis-Related Gene Signature for Predicting Biochemical Recurrence of Prostate Cancer
- (2021) Zhengtong Lv et al. Frontiers in Cell and Developmental Biology
- Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients
- (2021) A.A. Kulkarni et al. ESMO Open
- Towards Multidrug Adaptive Therapy
- (2020) Jeffrey West et al. CANCER RESEARCH
- Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor
- (2020) Marianne D. Sadar Expert Opinion on Drug Discovery
- Does sequencing order of antiandrogens in prostate cancer matter?
- (2020) Benjamin L. Maughan et al. Nature Reviews Urology
- Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of Neurological Disease in Mice
- (2020) Haibo Zhou et al. CELL
- Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer
- (2020) Pravien Rajaram et al. MOLECULES
- Stromal reactivity differentially drives tumour cell evolution and prostate cancer progression
- (2020) Ziv Frankenstein et al. Nature Ecology & Evolution
- A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer
- (2020) Rahul R. Aggarwal et al. CLINICAL CANCER RESEARCH
- Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer
- (2020) Tie Zhou et al. EUROPEAN JOURNAL OF CANCER
- Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer
- (2020) Kaylyn D. Tousignant et al. Cancer & Metabolism
- Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial
- (2020) Andrew J. Armstrong et al. EUROPEAN UROLOGY
- Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
- (2020) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer
- (2020) Alicia K. Morgans et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model
- (2020) Ahmed F. Salem et al. Cancers
- The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives
- (2020) Nicole Brighi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Cardiovascular Complications of Prostate Cancer Treatment
- (2020) Michał Wilk et al. Frontiers in Pharmacology
- A New Tool for CRISPR-Cas13a-Based Cancer Gene Therapy
- (2020) Jinliang Gao et al. Molecular Therapy-Oncolytics
- Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer
- (2020) Xumin Zhou et al. PHARMACOLOGICAL RESEARCH
- N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway
- (2019) Yu Yin et al. Molecular Cancer
- The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis
- (2019) Wenjuan Mei et al. Cancers
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Androgen receptor plasticity and its implications for prostate cancer therapy
- (2019) Oliver Snow et al. CANCER TREATMENT REVIEWS
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- SF3B2-mediated RNA splicing drives human prostate cancer progression
- (2019) Norihiko Kawamura et al. CANCER RESEARCH
- Molecular determinants for enzalutamide-induced transcription in prostate cancer
- (2019) Fuwen Yuan et al. NUCLEIC ACIDS RESEARCH
- Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer
- (2019) Elisa M. Ledet et al. ONCOLOGIST
- Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
- (2019) Daniel J Khalaf et al. LANCET ONCOLOGY
- A review of prostate cancer treatment impact on the CNS and cognitive function
- (2019) Charles Ryan et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors
- (2018) Silvana Konermann et al. CELL
- The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer
- (2018) Roberto Iacovelli et al. Clinical Genitourinary Cancer
- Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
- (2018) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Biallelic tumor suppressor loss and DNA repair defects in de novo small cell prostate cancer
- (2018) Edmund CP Chedgy et al. JOURNAL OF PATHOLOGY
- Androgen Receptor–Targeted Treatments for Prostate Cancer: 35 Years’ Progress with Antiandrogens
- (2018) E. David Crawford et al. JOURNAL OF UROLOGY
- Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements
- (2018) Michael Kosicki et al. NATURE BIOTECHNOLOGY
- p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells
- (2018) Robert J. Ihry et al. NATURE MEDICINE
- CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
- (2018) Emma Haapaniemi et al. NATURE MEDICINE
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
- (2018) Matti Annala et al. Cancer Discovery
- Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure
- (2018) Susan Slovin et al. JAMA Oncology
- Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer
- (2018) Athanasios E. Dellis et al. EXPERT OPINION ON PHARMACOTHERAPY
- Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis
- (2017) Jianhong Zhu et al. Expert Review of Anticancer Therapy
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer
- (2017) Ping Mu et al. SCIENCE
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
- (2017) Sheng Yu Ku et al. SCIENCE
- The Mediator Complex: At the Nexus of RNA Polymerase II Transcription
- (2017) Célia Jeronimo et al. TRENDS IN CELL BIOLOGY
- Emerging Variants of Castration-Resistant Prostate Cancer
- (2017) Panagiotis J. Vlachostergios et al. Current Oncology Reports
- Structure of the homodimeric androgen receptor ligand-binding domain
- (2017) Marta Nadal et al. Nature Communications
- Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
- (2017) Jingsong Zhang et al. Nature Communications
- Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials
- (2017) Raphael B. Moreira et al. Oncotarget
- Clinical relevance of androgen receptor alterations in prostate cancer
- (2017) Emma Jernberg et al. Endocrine Connections
- N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
- (2016) John K. Lee et al. CANCER CELL
- Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
- (2016) Y. C. Yang et al. CLINICAL CANCER RESEARCH
- Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
- (2016) Matthew R. Smith et al. EUROPEAN UROLOGY
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
- (2016) David F. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance
- (2016) Yang Zhan et al. MOLECULAR CANCER RESEARCH
- The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
- (2016) Stefan Prekovic et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
- (2016) E. S. Antonarakis et al. ONCOLOGIST
- Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
- (2016) Christine Henzler et al. Nature Communications
- Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes
- (2015) D. Xu et al. CANCER RESEARCH
- Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer
- (2015) Consuelo Buttigliero et al. CANCER TREATMENT REVIEWS
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms
- (2015) Margaret M Centenera et al. ENDOCRINE-RELATED CANCER
- Long-term Safety and Antitumor Activity in the Phase 1–2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer
- (2015) Celestia S. Higano et al. EUROPEAN UROLOGY
- The evolutionary history of lethal metastatic prostate cancer
- (2015) Gunes Gundem et al. NATURE
- Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
- (2015) Aaron Balog et al. ACS Medicinal Chemistry Letters
- Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth
- (2015) Yi-Ping Zhu et al. Oncotarget
- The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7
- (2015) Jacqueline Stockley et al. Scientific Reports
- Abstract 614: Proxalutamide (GT0918), a potent androgen receptor pathway inhibitor
- (2015) Youzhi Tong et al. CANCER RESEARCH
- Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
- (2015) Bo Cao et al. Oncotarget
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- Is there an antiandrogen withdrawal syndrome with enzalutamide?
- (2014) Alejo Rodriguez-Vida et al. BJU INTERNATIONAL
- Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer
- (2014) Z. Chen et al. EMBO JOURNAL
- Selectively Targeting the DNA-binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer
- (2014) Kush Dalal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer
- (2014) Dayong Wu et al. NUCLEIC ACIDS RESEARCH
- GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex
- (2014) Bin He et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Is there an anti-androgen withdrawal syndrome for enzalutamide?
- (2014) Christoph A. J. von Klot et al. WORLD JOURNAL OF UROLOGY
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
- (2013) H.-L. Tan et al. CLINICAL CANCER RESEARCH
- TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer
- (2013) M. D. Nyquist et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Epigenetic Repression of miR-31 Disrupts Androgen Receptor Homeostasis and Contributes to Prostate Cancer Progression
- (2012) P.-C. Lin et al. CANCER RESEARCH
- Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
- (2012) R. Hu et al. CANCER RESEARCH
- FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells
- (2012) B. Sahu et al. CANCER RESEARCH
- Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
- (2012) Himisha Beltran et al. EUROPEAN UROLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression
- (2012) Y Li et al. ONCOGENE
- Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression
- (2011) Y. Li et al. CANCER RESEARCH
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
- (2010) D. Rathkopf et al. CLINICAL CANCER RESEARCH
- The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression
- (2010) Ankur Sharma et al. JOURNAL OF CLINICAL INVESTIGATION
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
- (2010) William R. Foster et al. PROSTATE
- Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
- (2009) R. M. Attar et al. CANCER RESEARCH
- Increased Expression of Androgen Receptor Sensitizes Prostate Cancer Cells to Low Levels of Androgens
- (2009) K. K. Waltering et al. CANCER RESEARCH
- Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer
- (2009) M. A. Leversha et al. CLINICAL CANCER RESEARCH
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started